Akademik Veri Yönetim Sistemi
International Journal of Medical Biochemistry, cilt.1, sa.1, ss.44-51, 2018 (TRDizin)
The clinical diagnosis of heart failure (HF) is based on a history and a physical examination. Circulating molecules, suchas troponin, B-type natriuretic peptide, and N-terminal pro-B-type natriuretic peptide are useful in the management ofHF. Recently, it has been reported that a new biomarker, suppression of tumorigenicity (ST2), was associated with theprognosis of HF. ST2 is a cytokine and has 2 isoforms, a soluble (sST2) and a transmembrane receptor (ST2 ligand, orST2L). The effects of ST2 are related to it binding to interleukin 33, which is a proinflammatory cytokine. sST2 acts as adecoy receptor in these interactions. sST2 plays a role not only in the pathogenesis of HF, but also in the pathogenesisof atherosclerosis. Additionally, an increased blood concentration of sST2 has been reported in several diseases. Themost commonly used method is enzyme-linked immunoassay. However, there have been some methodological problemsin the analysis of sST2. The aim of this review was to explore the biology and analytical considerations of ST2 andits clinical importance in HF.